Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 22
Filtrar
1.
Hepatogastroenterology ; 57(102-103): 1215-9, 2010.
Artigo em Inglês | MEDLINE | ID: mdl-21410061

RESUMO

BACKGROUND/AIMS: The role of resistin, an adipocyte-secreted hormone, in insulin resistance and in inflammation is controversial. In chronic hepatitis C, insulin resistance, type 2 diabetes and liver steatosis are frequent and inconsistently correlated to circulating resistin levels. In this study we assessed if viral aetiology and host metabolic parameters influence serum resistin in patients with HCV- and HBV- related chronic hepatitis. METHODOLOGY: Serum resistin was measured by ELISA and correlated to viral aetiology, age, gender, BMI, HOMA-IR, liver steatosis, hepatitis staging and grading, blood glucose, triglycerides and cholesterol in 43 patients with chronic hepatitis C, in 16 with chronic hepatitis B and in 29 healthy controls. RESULTS: In both groups of patients resistin was significantly higher than in controls, with higher values in HBV- than in HCV-patients (p = 0.0007). Resistin levels were correlated to aetiology and, inversely, to age (p = 0.026), diabetes (p = 0.036) and steatosis (p = 0.029). Multiple regression analysis showed that resistin concentration was dependent only on the aetiology of liver disease (p = 0.001). CONCLUSIONS: In chronic viral hepatitis serum resistin levels are high and not associated with altered metabolic parameters or with the histological activity of the disease. The meaning of higher resistin in HBV- than in HCV- chronic hepatitis is unclear.


Assuntos
Hepatite B Crônica/sangue , Hepatite C Crônica/sangue , Doenças Metabólicas/diagnóstico , Resistina/sangue , Adulto , Idoso , Biomarcadores , Índice de Massa Corporal , Feminino , Humanos , Resistência à Insulina , Masculino , Pessoa de Meia-Idade
2.
Minerva Gastroenterol Dietol ; 53(4): 311-9, 2007 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-18043549

RESUMO

AIM: In several studies, attention is needed to one specific complication, in particularly to hepatocellular carcinoma, which modifies the natural history of liver cirrhosis. Thus, we performed a retrospective cohort analysis to clarify which complications, alone or in combination, are predictive factors of mortality in patients with viral or alcoholic cirrhosis without hepatocellular carcinoma. METHODS: Case records of 255 patients with decompensated viral or alcoholic cirrhosis between January 1990 and December 2000 were retrospectively analyzed. Relevant clinical and laboratory parameters, and their relationship to mortality, were studied. RESULTS: The mean duration of follow-up period was 29 months in which 178 patients (69.8%) died and 77 (31.8%) survived. None of the patients underwent liver transplantation. The cumulative mortality rate of patients with complicated cirrhosis was 38.8% after 1 year, 51.7% after 2 years, 61.1% after 3 years and 65.1% after 8 years. A multivariate Cox's model identified the following variables as significant: age (P=0.001), gastrointestinal bleeding (GB)-ascites combination (P=0.000), encephalopathy-GB-ascites (P=0.028), hepatorenal syndrome (HRS) (P=0.000), GB-spontaneous bacterial peritonitis (SBP) (P=0.001), alkaline phosphatase (ALP) (P=0.004) and the Child-Pugh score (P=0.000). CONCLUSION: The mortality in a group of patients with alcoholic cirrhosis is longer than in those with viral cirrhosis . Moreover, ascites in combination with other complications, HRS and hemorrage-SBP association are independent predictors of mortality in patients with complicated liver cirrhosis.


Assuntos
Cirrose Hepática Alcoólica/mortalidade , Cirrose Hepática/mortalidade , Cirrose Hepática/virologia , Adulto , Idoso , Idoso de 80 Anos ou mais , Estudos de Coortes , Seguimentos , Hepatite B/complicações , Hepatite B/diagnóstico , Hepatite C/complicações , Hepatite C/diagnóstico , Humanos , Estimativa de Kaplan-Meier , Cirrose Hepática/complicações , Cirrose Hepática/diagnóstico , Cirrose Hepática/etiologia , Cirrose Hepática Alcoólica/complicações , Cirrose Hepática Alcoólica/diagnóstico , Pessoa de Meia-Idade , Análise Multivariada , Prognóstico , Modelos de Riscos Proporcionais , Estudos Retrospectivos , Fatores de Risco , Fatores de Tempo
3.
Hepatogastroenterology ; 46(28): 2447-50, 1999.
Artigo em Inglês | MEDLINE | ID: mdl-10522017

RESUMO

BACKGROUND/AIMS: The impact of the treatment with interferon (IFN) on the natural history of chronic hepatitis C is not defined. The aim of this study was to evaluate the long term effect of the treatment in patients with chronic hepatitis C. METHODOLOGY: In 31 patients with chronic hepatitis C (9 with cirrhosis) consecutively treated with recombinant alpha 2a interferon (r alpha 2a IFN), the evolution of the disease at 10 years from the therapy was evaluated by means of upper endoscopy, liver ultrasonography (US), liver function tests and hepatitis C virus (HCV) viremia. RESULTS: Among 10/31 patients previously classified as responders, only 1 has signs of evolution to cirrhosis; HCV-RNA is still present in 2. Among 21 non-responder patients, 5 developed hepatocarcinoma (HCC) and 4 died during the follow-up; HCV-RNA is present in all the patients still alive. The 6 patients already cirrhotic when treated have clinical signs of progression to Child class B and C. The biochemical, ultrasonographical and endoscopical evaluation shows onset of cirrhosis in 7 of the others. CONCLUSIONS: Patients with chronic hepatitis C who respond to treatment with interferon have good outcome and rare evolution to cirrhosis. The treatment does not seem to influence the natural history of the disease in non-responders.


Assuntos
Hepatite C Crônica/tratamento farmacológico , Interferon-alfa/uso terapêutico , Adulto , Feminino , Seguimentos , Hepatite C Crônica/complicações , Humanos , Interferon alfa-2 , Cirrose Hepática/etiologia , Masculino , Pessoa de Meia-Idade , Proteínas Recombinantes
4.
Hepatogastroenterology ; 46(30): 3229-33, 1999.
Artigo em Inglês | MEDLINE | ID: mdl-10626191

RESUMO

BACKGROUND/AIMS: We retrospectively evaluated the long-term efficacy of interferon retreatment in patients with chronic hepatitis C, who did not have a sustained response to a 1st cycle of treatment. METHODOLOGY: Sixty-six patients, 43 non-responder and 23 relapser to alpha interferon treatment, were retreated with alpha interferon, 6 MU thrice weekly for 12 months. Response was defined as negative HCV viremia. Responders underwent long-term follow-up (27-43 months). RESULTS: The response rates were 14% and 35% at the end of retreatment, 7% and 22% at 6 months, and 2% and 13% at long-term follow-up in non-responders and relapsers respectively. The outcome of retreatment was not statistically influenced by age, cirrhosis, viral genotype, dose and duration of previous treatment. CONCLUSIONS: Interferon retreatment, for sustained viral eradication, is not effective in non-responders and useful in few relapsers. Whereas, retreatment could prove effective in slowing down the activity of the disease and reducing the incidence of hepatocarcinoma, since some relapses occur late during the follow-up. Therefore, retreatment should be confined to relapsers with contraindications to new more efficient therapeutic strategies.


Assuntos
Antivirais/uso terapêutico , Hepatite C Crônica/terapia , Interferon Tipo I/uso terapêutico , Adulto , Idoso , Alanina Transaminase/sangue , Feminino , Hepacivirus/genética , Hepacivirus/imunologia , Anticorpos Anti-Hepatite C/análise , Hepatite C Crônica/enzimologia , Hepatite C Crônica/virologia , Humanos , Masculino , Pessoa de Meia-Idade , RNA Viral/análise , Proteínas Recombinantes , Recidiva , Estudos Retrospectivos , Resultado do Tratamento , Viremia/terapia , Viremia/virologia
5.
Liver Transpl Surg ; 3(6): 598-603, 1997 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-9404960

RESUMO

Hepatic artery thrombosis occurs in 4% to 10% of adult patients and in up to 26% of children undergoing liver transplantation. Aspirin has been used to prevent this complication but may increase procedure-related and gastrointestinal bleeding. The aim of this study was to assess the efficacy and safety of low-dose aspirin in the prophylaxis of hepatic artery thrombosis. The histories of 529 patients who survived liver transplantation between September 1988 and December 1993 were reviewed retrospectively. The routine clinical practice followed until 1992 was to initiate oral aspirin therapy on the first postoperative day (81 mg daily in adults and 40 mg daily in children) as prophylaxis for vascular thrombosis. This was done in 354 patients. Aspirin was not administered to the remaining 175 patients. Hepatic artery thrombosis occurred in 13 patients treated with aspirin (3.7%) and in 7 patients not treated with aspirin (4.0%) (P = .85). Recipient age of younger than 2 years and low donor liver weight were the only factors that predisposed the patients to hepatic artery thrombosis. A total of 1,651 percutaneous liver biopsies were performed in this series, with 1,111 performed in patients treated with aspirin. Significant bleeding after liver biopsy occurred in 12 patients treated with aspirin (1.1%) and in 3 patients not treated with aspirin (0.6%) (P = .29). Gastrointestinal bleeding occurred in 66 patients treated with aspirin (18.9%) and in 23 patients not treated with aspirin (12.8%) (P = .08). Low-dose aspirin therapy is not shown to be effective in preventing hepatic artery thrombosis after liver transplantation. Although aspirin does not produce a statistically significant increase in the risk of bleeding after liver biopsy, there is a trend toward an increased incidence of gastrointestinal bleeding.


Assuntos
Aspirina/administração & dosagem , Artéria Hepática , Transplante de Fígado , Inibidores da Agregação Plaquetária/administração & dosagem , Complicações Pós-Operatórias/prevenção & controle , Trombose/prevenção & controle , Adolescente , Adulto , Idoso , Criança , Pré-Escolar , Feminino , Humanos , Lactente , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos
6.
Hepatogastroenterology ; 44(17): 1295-301, 1997.
Artigo em Inglês | MEDLINE | ID: mdl-9356842

RESUMO

BACKGROUND/AIMS: Enhanced hepatocellular display of class I HLA antigens together with rising serum beta-2-microglobulin (a subunit of class I HLA molecule) and transaminases is reported in patients with chronic hepatitis B during treatment with interferon as an index of immune lysis of virus infected cells. METHODOLOGY: We studied class I HLA antigens and beta-2-microglobulin display in the livers of 23 patients with chronic hepatitis C before and after a 12 month treatment with recombinant alpha interferon. Beta-2-microglobulin serum values were monitored. In all the patients before treatment, class I HLA antigens and beta-2-microglobulin were diffusely displayed in the bile duct epithelium, in the sinusoidal lining cells, in approximately 50% of the inflammatory cells and in the hepatocyte membrane with marked staining in the areas of periportal and lobular necrosis. RESULTS: At the end of the treatment, class I HLA antigens and beta-2-microglobulin were no longer or only faintly detectable in the hepatocytes of 12 patients who showed clinical and histological improvement. The immunohistochemical pattern was unchanged in the 11 patients who did not respond to the therapy. Baseline serum beta-2-microglobulin values were high in all the patients and decreased significantly only in the group of responders. No peaks of transaminases were registered. CONCLUSIONS: The disappearance or reduction of HLA hepatocellular display without acute increase of serum beta-2-microglobulin values and transaminases during successful treatment with interferon in chronic hepatitis C suggests a clearance of the virus due to direct antiviral rather than immunologically mediated mechanism.


Assuntos
Antivirais/uso terapêutico , Hepatite C Crônica/imunologia , Hepatite C Crônica/terapia , Antígenos de Histocompatibilidade Classe I/análise , Interferon-alfa/uso terapêutico , Fígado/imunologia , Microglobulina beta-2/análise , Alanina Transaminase/sangue , Aspartato Aminotransferases/sangue , Feminino , Humanos , Interferon alfa-2 , Masculino , Pessoa de Meia-Idade , Proteínas Recombinantes , Fatores de Tempo
7.
Hepatology ; 22(2): 389-94, 1995 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-7635405

RESUMO

Intrahepatic lymphocytic aggregates are observed in chronic hepatitis C as well as in autoimmune chronic hepatitis. Autoantibodies and autoimmune manifestations may occur in hepatitis C. It has been suggested that the lymphocytic aggregates play a role in the liver injury of chronic hepatitis C by an immune-mediated mechanism. We studied the occurrence of intrahepatic lymphocytic aggregates and of autoantibodies in a consecutive series of 128 patients with chronic hepatitis C. For the phenotypic characterization of the lymphocytic aggregates cryostat sections and microwaved paraffin embedded sections were immunostained with monoclonal antibodies directed against T cell subsets, B cells, killer/natural killer cells, follicular dendritic cells, and macrophages. Autoantibodies were tested by immunofluorescence (antinuclear, anti-smooth muscle, antimitochondrial) and by enzyme-linked immunosorbent assay (anti-soluble liver antigen, anti-liver/kidney microsome, anti-human receptor for asialoglycoprotein). Focal lymphocytic aggregates in portal tracts were observed in 76 of 128 (59%) patients. The cellular composition of the aggregates was constant: a core of B cells mixed with many T helper/inducer lymphocytes, and an outer ring was prominently formed by T suppressor/cytotoxic lymphocytes. A germinal center was rarely identifiable. The presence of lymphocytic aggregates was inversely correlated with the degree of fibrosis. Lymphocytic aggregates appeared more frequently in chronic persistent and chronic active hepatitis in comparison with cirrhosis and in the presence of bile duct damage. No correlation was found between lymphocytic aggregates and autoantibodies or other markers of autoimmunity. The lymphocytic aggregates are frequent in chronic hepatitis C. Their cellular composition is similar to that of primary lymphoid follicles in lymph nodes. Their presence does not seem to be correlated with features of autoimmunity.


Assuntos
Autoimunidade , Hepatite C/imunologia , Linfócitos/patologia , Adulto , Idoso , Autoanticorpos/sangue , Biomarcadores , Agregação Celular , Doença Crônica , Feminino , Hepatite C/patologia , Humanos , Imuno-Histoquímica , Contagem de Linfócitos , Subpopulações de Linfócitos , Linfócitos/imunologia , Masculino , Pessoa de Meia-Idade
8.
Gastroenterology ; 107(3): 799-804, 1994 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-8076767

RESUMO

BACKGROUND/AIMS: The asialoglycoprotein receptor (ASGPR) is an established, liver-specific autoantigen. This multicenter study investigated the specificity of anti-ASGPR autoantibodies for autoimmune hepatitis (AIH) in different ethnic groups. METHODS: Nine hundred fourteen sera from European, Japanese, and North American (U.S.) patients with chronic inflammatory liver disorders were tested. An enzyme-immunoassay using human ASGPR and a radioimmunoassay against rabbit ASGPR, performed independently on coded sera, were compared. RESULTS: The highest frequency (76%) of anti-human ASGPR was found in AIH patients (11/24 U.S.; 21/25 European; 28/30 Japanese), particularly in those with active disease before treatment (53/62, 85%), and decreased in titer with response to immunosuppressive therapy. These antibodies were found at low titers in 43 (11%) of 385 patients with viral hepatitis and in 25 (7.6%) of 328 patients with other chronic inflammatory liver disorders (P < 0.0005 compared with all AIH patients). Twenty of 37 sera tested by enzyme-immunoassay and radioimmunoassay were positive, and nine were negative for anti-ASGPR by both assays (78% concordance); six sera were exclusively positive on human substrate. CONCLUSIONS: Circulating anti-ASGPR autoantibodies are closely associated with autoimmune hepatitis independent of geographic or ethnic criteria. Two anti-ASGPR assays currently in use show high reliability.


Assuntos
Autoanticorpos/análise , Doenças Autoimunes/imunologia , Hepatite/imunologia , Receptores de Superfície Celular/imunologia , Receptor de Asialoglicoproteína , Aspartato Aminotransferases/sangue , Doença Crônica , Alemanha , Hepatite C/imunologia , Humanos , Técnicas Imunoenzimáticas , Itália , Japão , Prevalência , Análise de Regressão , Estados Unidos
9.
Minerva Gastroenterol Dietol ; 39(1): 1-5, 1993 Mar.
Artigo em Italiano | MEDLINE | ID: mdl-8357880

RESUMO

Hundred-forty-one patients, 78 affected by alcoholic liver cirrhosis and 63 by posthepatitic cirrhosis were studied in order to assess the degree of portal hypertension in liver cirrhosis of different etiology taking into account the developing stages of the disease. Etiological assessment was based on anamnesis, laboratory data, needle liver biopsy and patients of each group were divided into 3 subgroups (grade A, B, C) according to Child-Turcotte classification. A > 1.3 cm diameter of portal vein and a > 13 cm spleen size evaluated by means of real-time ultrasonography together with the occurrence of esophageal varices at endoscopy were considered as signs of portal hypertension. Our study shows that such signs are more frequent in patients affected by posthepatitic cirrhosis in comparison with those affected by alcoholic cirrhosis. If the severity of the disease was considered, at the early stage (grade A) no significant difference was reported in portal diameters while splenomegaly and esophageal varices appeared more frequent in posthepatitic cirrhosis. In grade B patients the increase of portal and spleen size proved significantly greater in posthepatitic cirrhosis whereas prevalence of esophageal varices was similar in the two groups. The lack of differences in the three considered parameters at the end stage of the disease may be due to severe changes in liver morphology actually similar in the 2 groups apart from etiological factors.


Assuntos
Hipertensão Portal/etiologia , Cirrose Hepática/complicações , Adulto , Idoso , Feminino , Humanos , Cirrose Hepática Alcoólica/complicações , Masculino , Pessoa de Meia-Idade , Índice de Gravidade de Doença
10.
Pathology ; 24(4): 243-6, 1992 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-1289764

RESUMO

To evaluate the histological effects of alpha Interferon (IFN) therapy, serial liver biopsy specimens from 30 patients with chronic hepatitis were studied. The biopsies were examined using a scoring system. After 12 mths of IFN therapy responders were 8 out of 11 HBV infected patients, 10 out of 12 HCV infected patients and only 1 out of 7 patients with cryptogenetic hepatitis. As spontaneous improvement of hepatic changes is infrequent, our data indicate that in terms of histological patterns interferon therapy is effective in chronic viral hepatitis.


Assuntos
Hepatite B/patologia , Hepatite C/patologia , Hepatite Crônica/patologia , Interferon-alfa/uso terapêutico , Hepatite B/terapia , Hepatite C/terapia , Hepatite Crônica/terapia , Humanos
11.
Nephron ; 61(3): 251-4, 1992.
Artigo em Inglês | MEDLINE | ID: mdl-1501725

RESUMO

Five viruses are responsible for the vast majority of cases of viral related hepatitis. They have been named hepatitis A virus (HAV), hepatitis B virus (HBV), hepatitis C virus (HCV), hepatitis D virus (HDV), hepatitis E virus (HEV). The more recent literature concerning the viral structure, the epidemiology, the serological identification, the clinical course and the prevention of each type of hepatitis is reviewed. HBV is not directly cytopathic. Hepatitis is a consequence of the destruction of the virus-infected cells. The efficient elimination of the virus relies on the viral antigenic determinants (HBs, pre-S1, pre-S2, HBc, HBe) and on the immune system of the host. The viral persistence may be caused by defect of the host immunity (interferon production, T and B lymphocyte function) or by factors related to the virus such as a genome mutation (lack of HBe formation). Some evidence suggesting an immunopathogenetic mechanism also for HCV, HDV and HAV is reported.


Assuntos
Hepatite Viral Humana/etiologia , Vírus de Hepatite/patogenicidade , Hepatite Viral Humana/epidemiologia , Hepatite Viral Humana/imunologia , Humanos
12.
Eur J Clin Invest ; 21(6): 586-91, 1991 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-1723384

RESUMO

Viral infection may play a role in alcoholic liver disease with histological features of chronic active hepatitis (CAH). Human leucocyte antigen (HLA) hepatocellular display is supposed to allow HLA-restricted T-lymphocyte cytotoxicity in chronic viral hepatitis. We studied the presence of serum anti-hepatitis C virus (HCV) antibodies, the hepatic HLA display and the composition of the mononuclear cell infiltrate in 16 patients with alcoholic liver disease and histological features of CAH and in 11 patients with alcohol-related degenerative changes. All patients were negative for hepatitis B virus (HBV) markers. Anti-HCV were tested by microplate ELISA. Class I HLA A, B, class II HLA DR, lymphocytes pan T, T helper/inducer, T suppressor/cytotoxic, B, and K NK cells were stained on liver cryostat sections by monoclonal antibodies and double indirect immunoperoxidase. Anti-HCV were present in all the patients with features of CAH and absent in those with only degenerative changes. In livers with features of CAH the mononuclear cell infiltrate consisted largely of T lymphocytes with marked prevalence of suppressor/cytotoxic cells in periportal and lobular areas. K NK cells were rare. Class I HLA, diffusely displayed on bile duct epithelium and on sinusoidal cells, also appeared on liver cells in the areas of periportal and lobular necrosis, namely on the hepatocytes in close contact with suppressor/cytotoxic T cells. In livers with only degenerative changes class I HLA were diffusely displayed on bile duct epithelium and on sinusoidal cells but absent on the hepatocytes. In all the specimens HLA DR antigens were expressed on sinusoidal and inflammatory cells.(ABSTRACT TRUNCATED AT 250 WORDS)


Assuntos
Antígenos HLA , Hepatite C/complicações , Hepatopatias Alcoólicas/etiologia , Adulto , Idoso , Feminino , Hepacivirus/imunologia , Anticorpos Anti-Hepatite/sangue , Anticorpos Anti-Hepatite C , Hepatite Crônica/complicações , Humanos , Leucócitos Mononucleares/imunologia , Leucócitos Mononucleares/patologia , Fígado/imunologia , Fígado/patologia , Hepatopatias Alcoólicas/imunologia , Hepatopatias Alcoólicas/patologia , Masculino , Pessoa de Meia-Idade , Linfócitos T Citotóxicos/imunologia , Linfócitos T Citotóxicos/patologia
13.
Eur J Epidemiol ; 3(4): 386-9, 1987 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-3691748

RESUMO

Sera from 619 HBsAg+ subjects living in eastern Sicily, consecutively collected from 1975-1985, were tested for markers of delta virus (HDV) infection: delta antigen (HDAg), antibodies to delta (anti-HDIg), and also for antibodies to HBcore of IgM type (anti-HBcIgM) and for the system HBe-anti-HBe. The subjects included 210 asymptomatic carriers, 238 patients with acute hepatitis and 171 patients with chronic liver disease. HDAg was not found in any of the samples. Anti-HD was found in 28/171 (16.3%) patients with chronic liver disease, in 13/210 (6%) asymptomatic HBsAg carriers and in 13/238 (5.4%) patients with acute hepatitis. None of our patients were drug addicts. One had a history of blood transfusion, and nine came from the same family unit. The prevalence of HDV infection in eastern Sicily is lower than in other areas of Sicily possibly because of the lower percentage of HBsAg carriers in the local population. Parenteral transmission of HDV does not seem to play a major role in our area, while the familial clustering suggests close body contact as an important way of spread.


Assuntos
Hepatite D/epidemiologia , Adolescente , Adulto , Idoso , Antígenos Virais/análise , Portador Sadio/imunologia , Feminino , Hepatite/complicações , Anticorpos Anti-Hepatite/análise , Hepatite D/complicações , Vírus Delta da Hepatite/imunologia , Antígenos da Hepatite delta , Humanos , Hepatopatias/complicações , Masculino , Pessoa de Meia-Idade , Sicília
14.
Minerva Med ; 76(41): 1907-10, 1985 Oct 27.
Artigo em Italiano | MEDLINE | ID: mdl-4058786

RESUMO

Anti-HBV core IgM antibodies (anti-HBc IgM) were tested by RIA in the sera from 269 patients with acute viral hepatitis (AVH), from 39 patients with chronic HBSAg+ hepatitis (CH) at various stage of evolution, in 41 asymptomatic HBsAg carriers and in 30 healthy volunteers. Anti-HBc IgM were found in 100/108 HBsAg+ AVH, in 6/161 HBsAg--AVH, in 9/39 with CH and only 1 asymptomatic HBsAg carrier. Among the chronic patients with anti-HBc IgM, 3 were HBeAg+ and 6 were anti-HBe+. The test of anti-HBc IgM results useful in the early aetiological diagnosis of acute hepatitis since it is always positive in HBV acute hepatitis even in the subjects who early seroconvert to anti-HBs; the absence of anti-HBc IgM in the HBsAg+ acute hepatitis suggests other overinfecting agents. The presence of anti-HBc IgM in CH seems not to be related to an active viral replication.


Assuntos
Anticorpos Anti-Hepatite B/análise , Hepatite Viral Humana/imunologia , Imunoglobulina M/análise , Doença Aguda , Adolescente , Adulto , Idoso , Criança , Pré-Escolar , Doença Crônica , Humanos , Masculino , Pessoa de Meia-Idade , Radioimunoensaio
15.
Hepatology ; 4(6): 1107-10, 1984.
Artigo em Inglês | MEDLINE | ID: mdl-6594313

RESUMO

The A, B, C and DR locus specificities of the human leukocyte antigens system (HLA) were determined in 45 delta-positive and 44 delta-negative Italian patients, all with HBsAg-positive chronic active liver disease; controls were 526 healthy Italian blood donors matched for age, sex and geographical origin. HLA-A, B, C gene frequencies were not significantly changed. In delta-positive patients, the frequencies of the DR locus specificities were: DR2, 37.8%; DR3, 20%; DR4, 11.1%. In the delta-negative patients, the frequencies were: DR2, 13.6%; DR3, 36.4%; DR4, 0%. Control frequencies were: DR2, 19.4%; DR3, 17.1%; DR4, 18.5%. The corrected p values of the differences between controls and delta-positive patients were: DR2, pc = 0.046; DR3, pc = NS (not significant); DR4, pc = NS. The corrected p values of the differences between controls and delta-negative patients were: DR2, pc = NS; DR3, pc = 0.03; DR4, pc = 0.002. These findings show that: (a) DR3, a genetic marker of autoimmunity, might assist the establishment of chronic HBsAg liver disease in the absence of delta superinfection; (b) DR2 is linked with failure to clear the delta agent, and (c) DR4 may protect from virus B persistence. Identification of adventitious factors such as delta may help uncover a subgroup of HBsAg carriers who are genetically predisposed to develop chronic liver disease.


Assuntos
Antígenos de Superfície da Hepatite B/análise , Hepatite B/genética , Antígenos de Histocompatibilidade Classe II/genética , Hepatopatias/genética , Viroses/genética , Adolescente , Adulto , Idoso , Doenças Autoimunes/genética , Criança , Doença Crônica , Vírus Defeituosos , Frequência do Gene , Antígenos HLA/genética , Antígenos HLA-DR , Hepatite Crônica/genética , Humanos , Pessoa de Meia-Idade
16.
Pediatr Med Chir ; 3(4): 277-9, 1981.
Artigo em Italiano | MEDLINE | ID: mdl-6806782

RESUMO

Little is known from the literature about the epidemiology of non A - non B hepatitis (NANB/H) in childhood. Aim of this study was to assess the prevalence of NANB/H in a consecutive series of children with acute viral hepatitis hospitalized over an one year's period. Thirty children, 9 females, aged 3-12 years, were studied. Serial blood samples were tested for HBsAg, anti-HBs, anti-HBc, anti-HAV (Abbott RIA), anti-HAV-IgM (Absorption Staph. aureus protein A), anti-EBV (Immunofluorescence), anti-CMV, anti-Herpes s. virus (complement fixation). The diagnosis of NANB/H was based on the absence of these markers. Nineteen patients (63,3%) had type A, and 5 (16,6%), had type B hepatitis. One child showed antibodies anti-Herpes with rising titer and 5 (16.6%), 2 females, were considered suffering from NANB/H. None of these patients had been injected or haemotransfuded; all but one came from rural ambient and two from the same family. Two children had an anicteric course. The illness lasted less than 30 days in all but one, who showed three peaks of transaminases and recovered after 70 days. These data show a prevalence of NANB/H in childhood greater than that elsewhere reported, while the absence of injections suggests a way of infection other than parenteral.


Assuntos
Hepatite C/epidemiologia , Hepatite Viral Humana/epidemiologia , Fatores Etários , Criança , Pré-Escolar , Feminino , Humanos , Itália , Masculino
17.
Hepatogastroenterology ; 28(2): 84-6, 1981 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-7216151

RESUMO

Lymphocyte subpopulations, both in peripheral blood and in liver specimens obtained with the Menghini needle, were evaluated by E and EA rosette technique in 30 patients with chronic active hepatitis (CAH), 8 patients with chronic persistent hepatitis (CPH), 11 patients with acute viral hepatitis (AVH) and 11 patients with normal histology or minimal non-specific changes. Circulating E-RCF concentration and percentage were significantly decreased in CAH and CPH patients. Only one patient with acute hepatitis had a decreased number of circulating E-RFC. The ratio of peripheral blood E-RFC to liver tissue E-RFC was decreased in the patient with chronic disease. In all the groups studied, the percentage of liver tissue and peripheral EA-RFC was similar to that found in the blood from controls. Significant differences were not found between patients with and without evidence for HB viral infection.


Assuntos
Hepatite/sangue , Fígado/patologia , Linfócitos , Doença Aguda , Doença Crônica , Humanos , Linfócitos/imunologia , Formação de Roseta
19.
Boll Soc Ital Biol Sper ; 56(20): 2123-8, 1980 Oct 30.
Artigo em Italiano | MEDLINE | ID: mdl-7459125

RESUMO

HBeAg and anti-HBe were tested by RIA (Abbott Kits) in 53 patients (38 HBsAg +) with acute viral hepatitis (AVH), in 27 patients (5 HBsAg +) with chronic active hepatitis (CAH), in 54 (8 HBsAg +) with cirrhosis, in 32 (17 HBsAg +) undergoing haemodialysis, in 6 HBsAg carriers and in 45 controls. Most of the patients with HBsAg + AVH were HBeAg + in the first week and showed seroconversion to anti-HBe within the fourth week of the illness. Two from the four patients still HBeAg + in the fourth week seroconverted later on and clinically recovered, one is still HBsAg +/HBeAg + in the seventh week and one developed CAH HBsAg +/HBeAg +. High prevalence of HBeAg was found in the haemodialysed (94%) and in the patients with CAH (80%) while anti-HBe was more frequent in the HBsAg carriers (100%) and in the cirrhotics (62,5%). Among the patients HBsAg-, none was HBeAg + while 18% with CAH, 21,7% with cirrhosis, 26,6% of the haemodialysed and 4% of the controls were anti-HBe +. Our data, relating to AVH, are similar to those referred in the literature, but show conversely high prevalence of anti-HBe in CAH and in cirrhosis.


Assuntos
Anticorpos Antivirais/análise , Anticorpos Anti-Hepatite B/análise , Antígenos da Hepatite B/análise , Antígenos E da Hepatite B/análise , Hepatopatias/imunologia , Doença Aguda , Portador Sadio/imunologia , Doença Crônica , Hepatite/imunologia , Hepatite Viral Humana/imunologia , Humanos , Cirrose Hepática/imunologia , Radioimunoensaio , Diálise Renal , Fatores de Tempo
20.
Boll Soc Ital Biol Sper ; 56(13): 1360-6, 1980 Jul 15.
Artigo em Italiano | MEDLINE | ID: mdl-7448030

RESUMO

The prevalence of the anti-HBc antibodies was studied in 54 patients with chronic liver disease and in a group of controls pair-matches. The meaning of the anti-HBc antibodies titer in the patients HBsAg negative is discussed. From our data, obtained by Radioimmunoassay, anti-HBc titers I:I000 seem to indicate an ongoing or recent viral replication, being probative, even in the absence of the HBsAg marker, for the viral etiology.


Assuntos
Anticorpos Anti-Hepatite B/análise , Hepatopatias/imunologia , Adolescente , Adulto , Idoso , Doença Crônica , Feminino , Antígenos de Superfície da Hepatite B/imunologia , Humanos , Cirrose Hepática/imunologia , Masculino , Pessoa de Meia-Idade , Radioimunoensaio
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA